Company Pharmagest Interactive Liquidnet
Stocks
FR0012882389
IT Services & Consulting
|
Real-time Estimate
Tradegate
19:24:37 20/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 34.02 EUR | -46.84% |
|
0.00% | - |
| 07-30 | Equasens Société anonyme Reports Group Revenue Results for the Second Quarter and First Half Ended 30 June 2026 | CI |
| 07-02 | Equasens Société Anonyme Announces Board Changes | CI |
Business description: Pharmagest Interactive
- pharmacy software publishing and integration (72.8%): software programs for managing data bases, information, inventories, orders, electronic care records, etc.;
- publishing of IT solutions for health and medical/social establishments (15.9%): publishing and integration of software packages for retirement homes, hospitals and care homes (software for managing admissions, billing, receipt and accounting management, care management, supply management, etc.);
- development of solutions and infrastructures for e-Health (6.2%): digital communication, telemedicine and telehealth solutions;
- software publishing for private practitioners and medical assistants (4.2%);
- development of financing solutions for leased goods (0.9%; Nanceo).
Net sales are distributed geographically as follows: France (87.5%), Italy (6.1%), Belgium (3%), Germany (2.5%), the United Kingdom (0.8%), and Ireland (0.1%).
Sales by Activity: Pharmagest Interactive
| Fiscal Period: December | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) | 2025 (EUR) |
|---|---|---|---|---|---|
Pharmagest | 143M | 156M | 163M | 163M | 172M |
Axigate Link | 27.99M | 32.61M | 31.12M | 32.12M | 37.59M |
E-Connect | - | - | - | - | 14.73M |
Medical Solutions | - | - | - | - | 9.99M |
Fintech | - | - | - | - | 1.98M |
Others | 22.19M | 25.17M | 25.94M | 21.14M | - |
Geographical breakdown of sales: Pharmagest Interactive
| Fiscal Period: December | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) | 2025 (EUR) |
|---|---|---|---|---|---|
France | 175M | 194M | 197M | 190M | 207M |
Italy | 9.53M | 10.4M | 11.88M | 12.43M | 14.34M |
Belgium | 3.05M | 5.64M | 6.41M | 6.52M | 7.14M |
Germany | 1.43M | 1.67M | 2.23M | 5.27M | 5.95M |
United Kingdom | - | 1.54M | 1.68M | 1.75M | 1.88M |
Other | - | - | - | - | 249K |
LUXEMBOURG | - | 81K | 47K | 24K | - |
Ireland | - | 243K | 393K | 335K | - |
Ireland and United Kingdom | 1.65M | - | - | - | - |
Belgium and Luxembourg | 2.6M | - | - | - | - |
Executive Committee: Pharmagest Interactive
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 57 | 22/04/2022 | |
| Director of Finance/CFO | - | 01/01/2023 | |
Damien Maringer
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/2018 |
| Corporate Officer/Principal | 56 | 29/06/2020 | |
Sabrina Gharbi
HRO | Human Resources Officer | - | 01/01/2019 |
Composition of the Board of Directors: Pharmagest Interactive
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 61 | 25/06/2026 | |
Anne Lhote
BRD | Director/Board Member | 58 | 16/06/2011 |
| Director/Board Member | 57 | 01/01/2013 | |
Sophie Mayeux
BRD | Director/Board Member | 69 | 22/06/2012 |
François Jacquel
BRD | Director/Board Member | 67 | 01/01/2011 |
| Director/Board Member | 49 | 27/06/2017 | |
| Director/Board Member | 56 | 29/06/2020 | |
| Director/Board Member | 62 | 01/06/2022 | |
Céline Dargent
BRD | Director/Board Member | 58 | 25/06/2026 |
Sylvie Ortillon
BRD | Director/Board Member | - | 25/06/2026 |
Company details: Pharmagest Interactive
Other IT Services & Consulting
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.18% | -0.21% | -2.44% | +66.32% | 223B | |
| -1.69% | -4.82% | +64.85% | +111.43% | 113B | |
| +1.78% | +4.52% | -26.85% | -39.13% | 112B | |
| +0.39% | -2.20% | -23.81% | -31.75% | 86.65B | |
| +1.00% | +3.97% | -28.55% | +4.44% | 60.85B | |
| +0.91% | -3.92% | -21.53% | -18.63% | 47.44B | |
| +3.77% | +1.13% | +4.41% | +113.22% | 39.48B | |
| +3.39% | -1.89% | +3.83% | +230.36% | 39.01B | |
| -0.48% | -3.44% | -10.68% | +12.33% | 37.5B | |
| Average | +0.97% | -1.92% | -4.53% | +49.84% | 84.35B | |
| Weighted average by Cap. | +0.46% | -1.00% | -1.51% | +44.18% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- EQS Stock
- Stock
- Company Pharmagest Interactive
Select your edition
All financial news and data tailored to specific country editions
